Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.

NCT01803438 is registered in ClinicalTrials.gov with Medtronic Cardiac Ablation Solutions as lead sponsor.

NCT NCT01803438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01803438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.
Lead sponsor
Medtronic Cardiac Ablation Solutions
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2014
Completion date
January 20, 2020
Enrollment
220 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic paroxysmal atrial fibrillation without clinically significant heart diseases